"Multi-omics technologies and synthetic immunology approaches to address human health and diseases – an emerging era of immunoengineering" by Dr. Kamal Mandal, Postdoctoral Scholar, Dept. of Laboratory Medicine, University of California San Francisco (UCSF)
The zoom link is
Time: 11:30 AM
The talk would consist of Dr. Mandal’s doctoral research where he describes the multi-omics approach he undertook to understand Sertoli cell maturation and differentiation. Using his unique multi-omics approach, making use of transcriptomics guided integrated proteomics and computational approach, he identified YY1 and ROR alpha as the lead transcription factors associated with Sertoli cell maturation and development.
Dr. Mandal would also talk about his postdoctoral research where he transitioned to synthetic immunology and made significant contributions to CAR-T therapy development for Acute Myeloid Leukemia (AML). Leveraging his proteomics expertise, he developed “structural surfaceomics” as a new proteomics technology platform to enable identification of protein-conformation based cancer antigen. This development is aimed to address the dearth of safe cancer targets which is a long-standing problem in cancer immunotherapy, including CAR-T therapy. Interestingly, structural surfaceomics is capable of venturing beyond the regular gene/protein expression-based target discovery, which happens to be the canonical approach. Using his technology platform, he successfully identified active conformation of integrin-β2 as an AML specific antigen and engineered a specific antibody against this antigen, using phage display library approach. He finally reconstructed this antibody into a single chain variable fragment (scFv), putting it in CAR-T format, developing a novel therapy for AML. Notably, AML is a challenging hematologic malignancy with no FDA approved CAR-T therapy yet, mainly due to toxicity concerns associated with the existing target candidates. Dr. Mandal has found his new CAR-T therapy highly efficacious against AML along with a good safety profile in pre-clinical trials.
Dr. Mandal did his PhD from National Institute of Immunology (NII) New Delhi where he worked on integrative multi-omics strategies to understand cellular differentiation using Sertoli cells as a model system. He then moved to University of California San Francisco (UCSF), for his postdoctoral training and started working on synthetic immunology to address novel immunotherapeutics development. Leveraging his extensive proteomics expertise, he developed a new technology platform called “structural surfaceomics” to enable identification of protein conformation-based cancer antigens for CAR-T therapy development. Using this technology, he successfully developed a novel CAR-T therapy against Acute Myeloid Leukemia. Dr. Mandal was recognized with the prestigious “Michelson Prize-2019” for his contribution to the field of synthetic immunology. He also received “Abstract Achievement Award-2022” from American Society of Hematology.